GlassScriptPhysician profile
Christina D Vlamos
NPI 1750739702
$3,529.42
in general payments reported to CMS, 2019-2025
31 companies · $717 in 2025
The $717 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,054 · 2022: $815 · 2023: $574 · 2024: $371 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $427.35 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $252.65 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $218.30 | 2021-2025 | |
| Orexo US, INC. | $183.18 | 2022-2025 | Zubsolv |
| Vanda Pharmaceuticals INC. | $156.42 | 2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $155.47 | 2021-2025 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $152.66 | 2022-2023 | |
| Dexcom, INC. | $132.79 | 2021-2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $104.56 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $97.74 | 2021-2023 | |
| Pfizer INC. | $90.31 | 2021 | |
| Axsome Therapeutics, INC. | $87.31 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.71 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.44 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $69.33 | 2021-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $66.95 | 2023-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.94 | 2025 | Caplyta |
| Almatica Pharma LLC | $51.16 | 2023-2025 | Loreev Xr, Gralise |
| Verona Pharma, INC. | $39.78 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $39.50 | 2022 | |
| Lilly USA, LLC | $37.48 | 2024 | Mounjaro, Zepbound |
| Eisai INC. | $36.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.30 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $22.31 | 2023 | Mitigare, Kloxxado |
| Astellas Pharma US INC | $22.23 | 2024 | Veozah |
| Biogen, INC. | $21.59 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.27 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.99 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.37 | 2024 | Voquezna |
| Philips North America LLC | $13.19 | 2024 | (Ck7) Extended Holter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Vlamos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.